Anebulo Pharmaceuticals, Inc. (ANEB) Key Metrics
ANEB valuation today
Trailing 12 months · as of October 21, 2026- Market cap
- $12.0M
- Enterprise value
- $3.2M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −1.89
ANEB key metrics, FY2020–FY2025
Fiscal year ended June 30, 2025 · U.S. dollarsANEB returns How much profit the business earns on the capital it uses.
ANEB per-share figures Results divided by the shares outstanding at year-end.
ANEB financial health Debt, liquidity and how easily interest is covered.
ANEB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ANEB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ANEB cash returned to shareholders
ANEB key metrics
FY2020–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.25 | −$0.32 | −$0.47 | −$0.29 | −$1.30 | −$0.01 |
| Operating cash flow per share | −$0.19 | −$0.31 | −$0.39 | −$0.23 | −$0.21 | −$0.01 |
| Free cash flow per share | −$0.19 | −$0.31 | −$0.39 | −$0.23 | −$0.21 | −$0.01 |
| Cash per share | $0.34 | $0.12 | $0.45 | $0.62 | $0.86 | $0.13 |
| Book value per share | $0.34 | $0.15 | $0.42 | $0.65 | $0.92 | $0.12 |
| Tangible book value per share | $0.34 | $0.15 | $0.42 | $0.65 | $0.92 | $0.12 |
| Dividends per share | — | — | — | — | $0.35 | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | — | — | — | — | — | $0.01 |
| Shares outstanding | 33.8M | 25.8M | 25.1M | 23.3M | 23.3M | 23.7M |
| Change in shares outstanding | +31.0% | +3.0% | +7.4% | 0.0% | −1.6% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −109.7% | −113.8% | −91.4% | −37.4% | −249.9% | −6.2% |
| Return on invested capital (ROIC) | — | — | — | −555.0% | −405.8% | — |
| Return on assets (ROA) | −104.6% | −104.2% | −86.1% | −36.7% | −245.1% | −5.8% |
| Return on tangible assets | −69.9% | −201.4% | −100.5% | −43.8% | −139.7% | −5.8% |
| Financial health | ||||||
| Total debt | — | — | — | — | — | $201,286 |
| Cash & short-term investments | $11.6M | $3.1M | $11.2M | $14.5M | $20.0M | $3.0M |
| Net debt | −$11.6M | −$3.1M | −$11.2M | −$14.5M | −$20.0M | −$2.8M |
| Debt / equity | — | — | — | — | — | 0.07 |
| Debt / assets | — | — | — | — | — | 0.07 |
| Current ratio | 53.36 | 13.46 | 10.92 | 30.40 | 89.61 | 13.53 |
| Quick ratio | 53.36 | 13.46 | 10.92 | 30.40 | 89.61 | 13.53 |
| Interest coverage | -24.1 | -54.9 | — | -931.7 | -307.1 | -134.8 |
| Working capital | $11.7M | $3.2M | $10.6M | $15.1M | $21.4M | $2.8M |
| Invested capital | $30,079 | $718,331 | −$646,053 | $518,429 | $1.4M | −$19,079 |
| Tangible asset value | $11.7M | $3.8M | $10.6M | $15.1M | $21.4M | $2.8M |
| Net current asset value | $11.5M | $3.2M | $10.6M | $15.1M | $21.4M | $2.8M |
| Graham net-net per share | $0.33 | $0.11 | $0.41 | $0.60 | $0.85 | $0.12 |
| Capital allocation | ||||||
| Dividends paid | — | — | — | — | $8.2M | — |
| Share buybacks (net) | — | — | — | — | $0 | $0 |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||||
| Receivables turnover | 0.00 | — | — | — | — | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $73,218 | — | — | — | — | $3,500 |
| Average payables | $190,300 | $345,486 | $457,686 | $245,438 | $55,024 | $0 |
| Average inventory | — | — | — | — | — | −$4 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ANEB's annual financial statements (latest annual report filed September 29, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ANEB valuation and financial ratios
Anebulo Pharmaceuticals earned a return on equity of −109.7% in fiscal 2025. The share count rose 42.6% from 23.7M to 33.8M over 5 years.
See the ANEB income statement, the ANEB chart for price history, or the ANEB stock overview for the latest quote and news.
ANEB key metrics FAQ
What is Anebulo Pharmaceuticals's return on equity?
Anebulo Pharmaceuticals's return on equity (ROE) was −109.7% in fiscal 2025: net income of -$8.5 million on average shareholders' equity of $7.7 million.
What is Anebulo Pharmaceuticals's current ratio?
Anebulo Pharmaceuticals's current ratio was 53.36 at the end of fiscal 2025: current assets were 53.36 times current liabilities.